Equibles does not estimate personal net worth.
Get an email with a short summary when Alx Oncology Holdings Inc publishes a filing, an earnings call transcript or a press release.
Get ALXO alertsHarish Shantharam is recorded as CFO at Alx Oncology Holdings Inc (ALXO). The newest filing on record that lists Harish Shantharam as CFO at Alx Oncology Holdings Inc (ALXO) is dated April 20, 2026. Alx Oncology Holdings Inc reported in an 8-K filed January 22, 2025 that Harish Shantharam was appointed Chief Financial Officer, effective January 21, 2025. The proxy statement of Alx Oncology Holdings Inc reports total compensation of $1,700,673 for Harish Shantharam in fiscal 2025, including a base salary of $464,479. Harish Shantharam has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Alx Oncology Holdings Inc on September 9, 2026. Alx Oncology Holdings Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Alx Oncology Holdings Inc includes Jason Lettmann (CEO and Board Member), Scott Garland (Chairman and Board Member), Michael Listgarten (General Counsel) and 7 others.
“Effective January 21, 2025, the Board of Directors (the "Board") of ALX Oncology Holdings Inc. (the "Company") appointed Harish Shantharam to the office of Chief Financial Officer to replace Shelly Pinto, who was serving as the Company's Interim Chief Financial Officer.”
“No, I mean, primarily the ORR, and we do believe we'll have some early color on durability. and with the data set and enrollment timeline we have. So I think we should have some early read on that as well.”
“2025 was a year of strategic prioritization and clinical validation for ALX, highlighted by the progress we made on our lead program, Evarpiset, and the clinical entry of our first ADC ALX 2004.”
“Here's a snapshot of our clinical pipeline. As we have communicated previously, we are pursuing a focused development strategy for evorpacept in combination with anticancer antibodies, given the consistent proof of concept that we have seen in various clinical studies with different monoclonal antibodies.”
Start not stated–present
Last confirmed April 20, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Alx Oncology Holdings Inc (ALXO) | Chief Financial Officer | $464,479 | $1,700,673 |
